Jefferies Financial Group Comments on Alaunos Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:TCRT)

Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) – Research analysts at Jefferies Financial Group issued their FY2027 earnings per share estimates for shares of Alaunos Therapeutics in a report released on Tuesday, March 7th. Jefferies Financial Group analyst C. Howerton anticipates that the company will post earnings of ($0.42) per share for the year. The consensus estimate for Alaunos Therapeutics’ current full-year earnings is ($0.20) per share.

Alaunos Therapeutics Price Performance

Shares of Alaunos Therapeutics stock opened at $0.59 on Thursday. The stock has a market cap of $127.55 million, a P/E ratio of -3.28 and a beta of 0.16. The stock’s 50 day simple moving average is $0.67 and its 200-day simple moving average is $1.19. Alaunos Therapeutics has a 1-year low of $0.41 and a 1-year high of $4.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Janney Montgomery Scott LLC purchased a new position in Alaunos Therapeutics in the second quarter worth approximately $101,000. Steward Partners Investment Advisory LLC purchased a new position in Alaunos Therapeutics in the second quarter worth approximately $45,000. Y Intercept Hong Kong Ltd purchased a new position in Alaunos Therapeutics in the second quarter worth approximately $31,000. Oppenheimer & Co. Inc. purchased a new position in Alaunos Therapeutics in the second quarter worth approximately $56,000. Finally, Nicolet Advisory Services LLC purchased a new position in Alaunos Therapeutics in the second quarter worth approximately $30,000. 34.36% of the stock is currently owned by institutional investors and hedge funds.

Alaunos Therapeutics Company Profile

(Get Rating)

Alaunos Therapeutics, Inc is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs.